These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21203958)

  • 1. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
    Lou Z; Zhang X
    Protein Cell; 2010 May; 1(5):435-42. PubMed ID: 21203958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tuberculosis structural genomics consortium: a structural genomics approach to drug discovery.
    Musa TL; Ioerger TR; Sacchettini JC
    Adv Protein Chem Struct Biol; 2009; 77():41-76. PubMed ID: 20663481
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
    Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
    Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing the structural coverage of tuberculosis drug targets.
    Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
    Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. targetTB: a target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis.
    Raman K; Yeturu K; Chandra N
    BMC Syst Biol; 2008 Dec; 2():109. PubMed ID: 19099550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
    Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
    Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colworth prize lecture 2016: exploiting new biological targets from a whole-cell phenotypic screening campaign for TB drug discovery.
    Moynihan PJ; Besra GS
    Microbiology (Reading); 2017 Oct; 163(10):1385-1388. PubMed ID: 28893361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High throughput crystallography of TB drug targets.
    Murillo AC; Li HY; Alber T; Baker EN; Berger JM; Cherney LT; Cherney MM; Cho YS; Eisenberg D; Garen CR; Goulding CW; Hung LW; Ioerger TR; Jacobs WR; James MN; Kim C; Krieger I; Lott JS; Sankaranarayanan R; Segelke BW; Terwilliger TC; Wang F; Wang S; Sacchettini JC
    Infect Disord Drug Targets; 2007 Jun; 7(2):127-39. PubMed ID: 17970224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TB Structural Genomics Consortium: a decade of progress.
    Chim N; Habel JE; Johnston JM; Krieger I; Miallau L; Sankaranarayanan R; Morse RP; Bruning J; Swanson S; Kim H; Kim CY; Li H; Bulloch EM; Payne RJ; Manos-Turvey A; Hung LW; Baker EN; Lott JS; James MN; Terwilliger TC; Eisenberg DS; Sacchettini JC; Goulding CW
    Tuberculosis (Edinb); 2011 Mar; 91(2):155-72. PubMed ID: 21247804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterial genomics and structural bioinformatics: opportunities and challenges in drug discovery.
    Waman VP; Vedithi SC; Thomas SE; Bannerman BP; Munir A; Skwark MJ; Malhotra S; Blundell TL
    Emerg Microbes Infect; 2019; 8(1):109-118. PubMed ID: 30866765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH; Smith PW
    Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium tuberculosis: a model system for structural genomics.
    Smith CV; Sacchettini JC
    Curr Opin Struct Biol; 2003 Dec; 13(6):658-64. PubMed ID: 14675542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteins with complex architecture as potential targets for drug design: a case study of Mycobacterium tuberculosis.
    Mészáros B; Tóth J; Vértessy BG; Dosztányi Z; Simon I
    PLoS Comput Biol; 2011 Jul; 7(7):e1002118. PubMed ID: 21814507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural genomics of Mycobacterium tuberculosis: a preliminary report of progress at UCLA.
    Goulding CW; Perry LJ; Anderson D; Sawaya MR; Cascio D; Apostol MI; Chan S; Parseghian A; Wang SS; Wu Y; Cassano V; Gill HS; Eisenberg D
    Biophys Chem; 2003 Sep; 105(2-3):361-70. PubMed ID: 14499904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclipostins and cyclophostin analogs inhibit the antigen 85C from
    Viljoen A; Richard M; Nguyen PC; Fourquet P; Camoin L; Paudal RR; Gnawali GR; Spilling CD; Cavalier JF; Canaan S; Blaise M; Kremer L
    J Biol Chem; 2018 Feb; 293(8):2755-2769. PubMed ID: 29301937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential impact of structural genomics on tuberculosis drug discovery.
    Arcus VL; Lott JS; Johnston JM; Baker EN
    Drug Discov Today; 2006 Jan; 11(1-2):28-34. PubMed ID: 16478688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.